Polivy logo

A clinical benefit full of life

POLIVY-R-CHP: the first clinically meaningful improvement over a standard of care that held for 20 years1-13

Watch experts perspectives

Specialist views covering a range of POLARIX trial topics

A Smiling grey-haired man wearing a blue button-up shirt.

Dr Hervé Tilly

University of Rouen, France

A smiling male medical professional wearing a white lab coat and a blue necktie.

Prof. Christopher Flowers

MD, Anderson Cancer Center, University of Texas

A portrait of a smiling middle-aged man in a suit and tie.

Dr Franck Morschhauser

MD, PhD Professor of Hematology,
University of Lille

A smiling blonde woman with short hair wearing a black top and a pink cardigan.

Dr Laurie H. Sehn

MD, MPH Clinical Assistant
Professor with the BC Cancer Agency and University
of British Columbia

Illustration of diverse people standing in the shape of the number 27 next to a large percent symbol.

reduced risk of progression, relapse, or death with 

POLIVY-R-CHP vs R-CHOP.1,*

That means more hope for the future, and more freedom from the threat of disease.

POLARIX Trial

What is the POLARIX trial?

A phase III trial to compare the efficacy and safety of polatuzumab vedotin in combination with R-CHP vs R-CHOP in 1L DLBCL1

READ MORE

Efficacy

Was a meaningful benefit seen for 1L DLBCL patients?

The POLIVY-R-CHP regimen demonstrated a clinically meaningful progression-free survival benefit over R-CHOP1

READ MORE

Safety

Were there any safety concerns?

The overall safety profile of POLIVY-R-CHP is similar to that of R-CHOP and consistent with the known risk of the individual study drugs1

READ MORE

“The new regimen should reduce the risk of relapse and help patients avoid intensive treatments such as stem cell transplantation and chimeric antigen receptor T-cell therapy.”14

– Dr Gilles Salles, MD, PhD

Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center

A diverse group consisting of a coach holding a clipboard, a man dribbling a basketball, and a younger player.
A diverse group consisting of a coach holding a clipboard, a man dribbling a basketball, and a younger player.

About POLIVY

Considering using
POLIVY-R-CHP for your patients?

Learn more about dosage, administration, and mechanism of action

read more

*Stratified hazard ratio 0.73; 95% CI, 0.57–0.95; P=0.021
1L=first line; DLBCL=diffuse large B-cell lymphoma; POLIVY-R-CHP=polatuzumab vedotin + rituximab, cyclophosphamide, doxorubicin, prednisone; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone.

 

References:

  1. Tilly H, et al. N Engl J Med. 2022;386:351-63.
  2. Aurer I, et al. Eur J Haematol. 2011;86:111-6..
  3. Bartlett NL, et al. J Clin Oncol. 2019;37:1790-9.
  4. Coiffier B, et al. N Engl J Med. 2002;346:235-42.
  5. Cunningham D, et al. Lancet. 2013;381:1817-26.
  6. Davies A, et al. Lancet Oncol. 2019;20:649-62.
  7. Iacoboni G, et al. Ann Oncol. 2018;29:1120-9.
  8. Jaeger U, et al. Haematologica. 2015;100:955-63.
  9. Seymour JF, et al. Haematologica. 2014;99:1343-9.
  10. Vitolo U, et al. J Clin Oncol. 2017;35:3529-37.
  11. Vitolo U, et al. Hematol Oncol. 2019;37:36-7.
  12. Witzig TE, et al. Ann Oncol. 2018;29:707-14.
  13. Younes A, et al. J Clin Oncol. 2019;37:1285-95.
  14. ASCO Post. 2021 [cited 2022 15 July]. Available from: https://ascopost.com/news/december-2021/polarix-pola-r-chp-vs-r-chop-for-previously-untreated-patients-with-dlbcl/.